Abstract:The Journal of Clinical PharmacologyAccepted Articles COMMENTARYFree Access Exploring the knowledge gaps in infant drug exposure from human milk: A clinical pharmacology perspective Daphne Guinn PhD, Corresponding Author Daphne Guinn PhD Daphne.Guinn@fda.hhs.gov Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA Correspondence Daphne Guinn, PhD, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Email: Daphne.Guinn@fda.hhs.govSearch for more papers by this authorMichelle A. Pressly PhD, Michelle A. Pressly PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorZhichao Liu PhD, Zhichao Liu PhD National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas, USASearch for more papers by this authorCarrie Ceresa PharmDMPH, Carrie Ceresa PharmDMPH Division of Pediatrics and Maternal Health, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Office of New Drugs, Center for Drug Evaluation and Research, Silver Spring, Maryland, USASearch for more papers by this authorSherbet Samuels PhD, Sherbet Samuels PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorYow-Ming Wang PhD, Yow-Ming Wang PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorRajanikanth Madabushi PhD, Rajanikanth Madabushi PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorStephan Schmidt PhD, Stephan Schmidt PhD Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, United StatesSearch for more papers by this authorElimika Pfuma Fletcher PharmDPhD, Elimika Pfuma Fletcher PharmDPhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this author Daphne Guinn PhD, Corresponding Author Daphne Guinn PhD Daphne.Guinn@fda.hhs.gov Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA Correspondence Daphne Guinn, PhD, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Email: Daphne.Guinn@fda.hhs.govSearch for more papers by this authorMichelle A. Pressly PhD, Michelle A. Pressly PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorZhichao Liu PhD, Zhichao Liu PhD National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas, USASearch for more papers by this authorCarrie Ceresa PharmDMPH, Carrie Ceresa PharmDMPH Division of Pediatrics and Maternal Health, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, Office of New Drugs, Center for Drug Evaluation and Research, Silver Spring, Maryland, USASearch for more papers by this authorSherbet Samuels PhD, Sherbet Samuels PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorYow-Ming Wang PhD, Yow-Ming Wang PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorRajanikanth Madabushi PhD, Rajanikanth Madabushi PhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this authorStephan Schmidt PhD, Stephan Schmidt PhD Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, United StatesSearch for more papers by this authorElimika Pfuma Fletcher PharmDPhD, Elimika Pfuma Fletcher PharmDPhD Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USASearch for more papers by this author First published: 10 November 2022 https://doi.org/10.1002/jcph.2177 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as https://doi.org/10.1002/jcph.2177 AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Accepted ArticlesAccepted, unedited articles published online and citable. The final edited and typeset version of record will appear in the future. RelatedInformation

Structural Studies on McN‐5652‐X (I), a High‐Affinity Ligand for the Serotonin Transporter in Mammalian Brain.

Structural studies on McN-5652-X, a high-affinity ligand for the serotonin transporter in mammalian brain

Several Concerns Arise when the Results Are Interpreted

Synthesis and Pharmacological Evaluation of (z)‐9‐(heteroarylmethylene)‐7‐azatricyclo[4.3.1.03,7]decanes: Thiophene Analogues As Potent Norepinephrine Transporter Inhibitors.

Plasticity of Fetal and Adult Cns Serotonergic Neurons - Role of Growth-Regulatory Factors

Correction to Discovery of Chromane-6-Sulfonamide Derivative as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.

Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor

Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter

Exploring the Knowledge Gaps in Infant Drug Exposure from Human Milk: A Clinical Pharmacology Perspective

Growth-Hormone Receptors - Their Structure, Location And Role

Complete NMR Assignment of Cyclic Octapeptide CTAP.

Simplifying Submission Requirements for the Journal of Medicinal Chemistry

ChemInform Abstract: Discovery and Total Synthesis of a New Estrogen Receptor Heterodimerizing Actinopolymorphol A from Actinopolymorpha Rutilus.

Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.

ChemInform Abstract: Total Syntheses of (‐)‐isoschizogamine and (‐)‐2‐Hydroxyisoschizogamine.

Special Issue of "medicinal Chemistry"

ChemInform Abstract: Asymmetric Synthesis of Β‐substituted Γ‐lactams Via Rhodium/Diene‐Catalyzed 1,4‐additions: Application to the Synthesis of (r)‐baclofen (V) and (r)‐rolipram (IV).

Corrrection to Discovery of Tetrahydropyrazolopyrimidine Carboxamide Derivatives As Potent and Orally Active Novel Antitubercular Agents

ChemInform Abstract: Marine Bacterial Inhibitors from the Sponge‐Derived Fungus Aspergillus Sp.

Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT 2 Receptor Agonist